FR2704391A1 - Nutritional supplement which can be taken orally to facilitate adaptation to daily stress - Google Patents
Nutritional supplement which can be taken orally to facilitate adaptation to daily stress Download PDFInfo
- Publication number
- FR2704391A1 FR2704391A1 FR9305201A FR9305201A FR2704391A1 FR 2704391 A1 FR2704391 A1 FR 2704391A1 FR 9305201 A FR9305201 A FR 9305201A FR 9305201 A FR9305201 A FR 9305201A FR 2704391 A1 FR2704391 A1 FR 2704391A1
- Authority
- FR
- France
- Prior art keywords
- nutritional supplement
- magnesium
- stress
- facilitate adaptation
- daily stress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 13
- 230000006978 adaptation Effects 0.000 title claims abstract description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 18
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 16
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000011777 magnesium Substances 0.000 claims abstract description 11
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 11
- 229960003080 taurine Drugs 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 8
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 8
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 8
- 229940091250 magnesium supplement Drugs 0.000 claims abstract description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000011742 magnesium glycerophosphate Substances 0.000 claims description 4
- 235000001130 magnesium glycerophosphate Nutrition 0.000 claims description 4
- BHJKUVVFSKEBEX-UHFFFAOYSA-L magnesium;2,3-dihydroxypropyl phosphate Chemical compound [Mg+2].OCC(O)COP([O-])([O-])=O BHJKUVVFSKEBEX-UHFFFAOYSA-L 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 3
- 240000002900 Arthrospira platensis Species 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 229940082787 spirulina Drugs 0.000 claims description 3
- 208000008167 Magnesium Deficiency Diseases 0.000 description 4
- 235000004764 magnesium deficiency Nutrition 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010052813 Aerophagia Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
COMPLEMENT NUTRITIONNEL ABSORBABLE POUR FACILITER
L'ADAPTATION AU STRESS QUOTIDIEN.ABSORBABLE NUTRITIONAL SUPPLEMENT TO FACILITATE
ADAPTING TO DAILY STRESS.
L'invention concerne un complément nutritionnel absorbable pour faciliter l'adaptation au stress quotidien. The invention relates to an absorbable nutritional supplement to facilitate adaptation to daily stress.
Comme on le sait, la situation de stress résulte d'un débordement des capacités physiologiques d'adaptation face à des situations stressantes. As we know, the stressful situation results from an overflow of physiological capacities to adapt to stressful situations.
Ce débordement survient soit lorsque l'agression est trop forte, soit lorsque les capacités d'adaptation sont affaiblies. Il se traduit essentiellement par un inconfort psychologique, une baisse d'énergie, un affaiblissement des défenses immunitaires face aux infections, de l'aérophagie, des palpitations.This overflow occurs either when the aggression is too strong, or when the adaptive capacities are weakened. It mainly results in psychological discomfort, a drop in energy, a weakening of the immune defenses against infections, aerophagia, palpitations.
De la sorte, pouvoir contrôler le stress est non seulement une façon d'améliorer le confort personnel, mais constitue également une importante mesure de médecine préventive. In this way, being able to control stress is not only a way to improve personal comfort, but also constitutes an important measure of preventive medicine.
L'invention permet d'atteindre ces objectifs. Elle vise un complément nutritionnel absorbable qui se caractérise en ce qu'il contient en association de la taurine, de la vitamine B6, du magnésium et un excipient. The invention achieves these objectives. It targets an absorbable nutritional supplement which is characterized in that it contains in combination with taurine, vitamin B6, magnesium and an excipient.
Par "complément nutritionnel", on désigne un ensemble absorbable formant une supplémentation en micronutriments complétant l'alimentation quotidienne, qui permet à la fois d'agir sur un symptôme et en même temps de renforcer l'organisme. By "nutritional supplement" is meant an absorbable whole forming a micronutrient supplementation supplementing the daily diet, which allows both to act on a symptom and at the same time to strengthen the body.
Comme on le sait, le magnésium intervient lors de la production de l'énergie. La baisse du niveau d'énergie disponible s'accompagne d'une anxiété qui, elle-même, est consommatrice de magnésium. Ainsi, une personne qui présente des carences en magnésium "hyperréagit" au stress par des manifestations d'intensité disproportionnée augmentant ainsi son déficit en énergie et son anxiété. As we know, magnesium is involved in the production of energy. The drop in the level of available energy is accompanied by anxiety which, itself, consumes magnesium. Thus, a person who has magnesium deficiencies "hyperreacts" to stress by manifestations of disproportionate intensity, thus increasing his energy deficit and his anxiety.
On est donc en présence d'un cercle vicieux, puisque la carence en magnésium engendre le stress et le stress entraîne une carence accrue en magnésium. We are therefore in the presence of a vicious circle, since the magnesium deficiency generates stress and the stress leads to an increased magnesium deficiency.
Avantageusement en pratique, le magnésium se présente sous forme de glycérophosphate de magnésium, plus facile à assimiler. Advantageously in practice, magnesium is in the form of magnesium glycerophosphate, which is easier to assimilate.
La taurine, qui est un acide aminé, présente des propriétés complémentaires de celles du magnésium. Elle diminue l'excitabilité des cellules dans la plupart des organes, tels que le coeur et le cerveau. Elle facilite la fixation du magnésium et tamponne l'excès de calcium intracellulaire. "Ainsi, la taurine compense les effets d'un déficit en magnésium. Taurine, which is an amino acid, has properties complementary to those of magnesium. It decreases the excitability of cells in most organs, such as the heart and the brain. It facilitates the fixation of magnesium and buffers excess intracellular calcium. "Thus, taurine compensates for the effects of a magnesium deficiency.
La vitamine B6 est le co-facteur de la synthèse de la taurine. Elle est également nécessaire à la synthèse du G.A.B.A et de la sérotonine, qui sont deux neuro-transmetteurs anti-anxiogènes. La vitamine B6 n'agit que lorsqu'elle est activée et son activation dépend du magnésium. Vitamin B6 is the co-factor in the synthesis of taurine. It is also necessary for the synthesis of G.A.B.A and serotonin, which are two anti-anxiety neuro-transmitters. Vitamin B6 only works when activated and its activation depends on magnesium.
Ainsi, magnésium, taurine et vitamine B6 agissent en synergie entre eux pour concourrir à une action anti-stress originale. Thus, magnesium, taurine and vitamin B6 act in synergy between them to contribute to an original anti-stress action.
Comme excipient, on utilise avantageusement du dextrose stabilisé par du stéarate de magnésium et coloré par la poudre de spiruline. As excipient, use is advantageously made of dextrose stabilized with magnesium stearate and colored with spirulina powder.
Dans une forme d'exécution préférée, la composition nutritionnelle caractéristique de l'invention contient en pour cent en poids:
- 80 % de glycérophosphate de magnésium;
- 8,4 % de taurine;
- 0,1 % de vitamine B6;
-11,5 % d'excipient, par exemple:
.9,8% de dextrose; .1 I % de stéarate de magnésium;
.0,7% de poudre de spiruline.In a preferred embodiment, the nutritional composition characteristic of the invention contains in percent by weight:
- 80% magnesium glycerophosphate;
- 8.4% taurine;
- 0.1% vitamin B6;
-11.5% of excipient, for example:
.9.8% dextrose; .1 I% magnesium stearate;
0.7% spirulina powder.
Pour garantir l'intégrité des différents composés, on effectue avantageusement la formulation de la manière suivante. Dans un premier temps, on granule en phase humide les excipients et les principaux composés. Puis, dans un deuxième temps, on mélange en phase sèche les vitamines et les principes actifs fragiles. To guarantee the integrity of the various compounds, the formulation is advantageously carried out in the following manner. Initially, the excipients and the main compounds are granulated in the wet phase. Then, in a second step, vitamins and fragile active ingredients are mixed in the dry phase.
Le complément nutritionnel selon l'invention peut être absorbé sous forme de poudre, de gélules, de granules, et avantageusement de comprimés. The nutritional supplement according to the invention can be absorbed in the form of powder, capsules, granules, and advantageously tablets.
Ce complément nutritionnel, sous la forme de comprimés de 500 mg, peut être avalé à raison de deux comprimés respectivement le matin et le soir au cours du repas pendant deux à trois mois renouvelables. This nutritional supplement, in the form of tablets of 500 mg, can be swallowed at the rate of two tablets respectively in the morning and in the evening during the meal for two to three months renewable.
Le complément nutritionnel conforme à l'invention permet avantageusement:
- de faciliter l'adaptation au stress de tous ordres : physiques (surmenage, accident, fracture, opération chirurgicale) et psychologiques (soucis, situations conflictuelles, deuil, etc...) ;
- de compenser la vulnérabilité au stress, la nervosité, l'hyperémotivité, la tendance colérique chez l'enfant et l'adolescent;
- de compenser la vulnérabilité au stress chez la femme, en particulier sous pilule, lorsqu'elle souffre de troubles liés au cycle menstruel ou pendant la grossesse; ;
- de compenser la vulnérabilité au stress liée à la spasmophilie (hyperréactivité, nervosité, troubles du sommeil, fatigabilité, sensations de malaise, gorge serrée, fourmillements, contractures, crampes, tremblements, ballonnements, troubles du transit, palpitations, sueurs, etc..., tous ces symptômes étant en outre aggravés par le stress). The nutritional supplement according to the invention advantageously allows:
- to facilitate adaptation to stress of all kinds: physical (overwork, accident, fracture, surgical operation) and psychological (worries, conflict situations, mourning, etc.);
- to compensate for vulnerability to stress, nervousness, hyperemotivity, angry tendency in children and adolescents;
- to compensate for the vulnerability to stress in women, in particular on the pill, when they suffer from disorders linked to the menstrual cycle or during pregnancy; ;
- to compensate for the vulnerability to stress linked to spasmophilia (hyperreactivity, nervousness, sleep disturbances, tiredness, feelings of discomfort, tight throat, tingling, contractures, cramps, tremors, bloating, transit disorders, palpitations, sweating, etc.) ., all these symptoms being further aggravated by stress).
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9305201A FR2704391B1 (en) | 1993-04-27 | 1993-04-27 | Absorbable nutritional supplement to facilitate adaptation to daily stress. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9305201A FR2704391B1 (en) | 1993-04-27 | 1993-04-27 | Absorbable nutritional supplement to facilitate adaptation to daily stress. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2704391A1 true FR2704391A1 (en) | 1994-11-04 |
| FR2704391B1 FR2704391B1 (en) | 1995-06-02 |
Family
ID=9446661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9305201A Expired - Fee Related FR2704391B1 (en) | 1993-04-27 | 1993-04-27 | Absorbable nutritional supplement to facilitate adaptation to daily stress. |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2704391B1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT409218B (en) * | 2000-11-14 | 2002-06-25 | Red Bull Gmbh | Use of taurine for improving psychomotor performance and coordination |
| WO2003013495A1 (en) * | 2001-08-08 | 2003-02-20 | Smothers Don L | Formulation and method for reduction of stress in meat-producing animals |
| EP1541041A1 (en) * | 2003-12-10 | 2005-06-15 | Synergia Holding | Pharmaceutical and/or dietary compositions against stress |
| CN111315373A (en) * | 2017-10-13 | 2020-06-19 | 瑟纳法姆工业合成有限公司 | Compounds and compositions for the prevention and/or treatment of central nervous system diseases characterized by a decrease in neuronal plasticity, in particular a decrease in synaptic plasticity |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980168A (en) * | 1989-10-13 | 1990-12-25 | Natrol, Inc. | Dietary supplement for children |
| WO1991011117A2 (en) * | 1990-02-05 | 1991-08-08 | Board Of Regents, The University Of Texas System | Dietary supplements comprising vitamins and minerals |
| WO1993002682A1 (en) * | 1991-08-06 | 1993-02-18 | Labco Pharmaceuticals, Inc. | Method and compositions for reducing craving for alcohol and stimulants |
-
1993
- 1993-04-27 FR FR9305201A patent/FR2704391B1/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980168A (en) * | 1989-10-13 | 1990-12-25 | Natrol, Inc. | Dietary supplement for children |
| WO1991011117A2 (en) * | 1990-02-05 | 1991-08-08 | Board Of Regents, The University Of Texas System | Dietary supplements comprising vitamins and minerals |
| WO1993002682A1 (en) * | 1991-08-06 | 1993-02-18 | Labco Pharmaceuticals, Inc. | Method and compositions for reducing craving for alcohol and stimulants |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT409218B (en) * | 2000-11-14 | 2002-06-25 | Red Bull Gmbh | Use of taurine for improving psychomotor performance and coordination |
| WO2003013495A1 (en) * | 2001-08-08 | 2003-02-20 | Smothers Don L | Formulation and method for reduction of stress in meat-producing animals |
| EP1541041A1 (en) * | 2003-12-10 | 2005-06-15 | Synergia Holding | Pharmaceutical and/or dietary compositions against stress |
| FR2863497A1 (en) * | 2003-12-10 | 2005-06-17 | Synergia Holding | NEW PHARMACEUTICAL AND / OR DIETETIC COMPOSITIONS AGAINST STRESS |
| CN111315373A (en) * | 2017-10-13 | 2020-06-19 | 瑟纳法姆工业合成有限公司 | Compounds and compositions for the prevention and/or treatment of central nervous system diseases characterized by a decrease in neuronal plasticity, in particular a decrease in synaptic plasticity |
| US20220008455A1 (en) * | 2017-10-13 | 2022-01-13 | Synapharm Industrial Synthesis | Compound and Composition for Use in the Preventive and/or Curative Treatment of Diseases of the Central Nervous System Characterised by a Decline in Neuronal Plasticity, in Particular Characterised by a Decline in Synaptic Plasticity |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2704391B1 (en) | 1995-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5932624A (en) | Vitamin supplement composition | |
| US5514382A (en) | Daily vitamin and mineral supplement for women | |
| RU2152216C1 (en) | Composition containing dietetic additives (versions) | |
| US5976568A (en) | Modular system of dietary supplement compositions for optimizing health benefits and methods | |
| RU2381025C2 (en) | Composition for eye treatment containing omega-3 fatty acids and omega-6 fatty acids | |
| JPH06192105A (en) | Medical preparation for lowering level of homocysteine | |
| US20100098779A1 (en) | Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects | |
| WO2008079876A1 (en) | Methods and kits for co-administration of nutritional supplements | |
| US9072693B2 (en) | Micronutrient supplement with calcium, vitamin D or calcium and vitamin D combination for premenstrual/menstrual relief | |
| IL139681A0 (en) | Pharmaceutical compositions containing vitamin b6 | |
| WO2000066133A1 (en) | Dietary supplement | |
| Manzoni et al. | Skin changes after bariatric surgery | |
| US20090220619A1 (en) | Nutritional formulation | |
| US6605646B2 (en) | Vitamin supplement composition | |
| KR20210060717A (en) | Oral solution powder composition for fatigue reduction and method of preparing the same | |
| FR2704393A1 (en) | Nutritional supplement which can be taken orally to optimise growth and maintain robustness of bones | |
| FR2704391A1 (en) | Nutritional supplement which can be taken orally to facilitate adaptation to daily stress | |
| US20130064924A1 (en) | Nutritional supplement for use under physiologically stressful conditions | |
| JPH11255656A (en) | Therapeutic composition for atopic dermatitis | |
| FR2737849A1 (en) | Orally administered food supplement for adults of over forty | |
| FR2704392A1 (en) | Nutritional supplement which can be taken orally to improve and optimise individuals' levels of physical and mental activity | |
| Theisler | Adjuvant medical care | |
| Murray | The pill book guide to natural medicines: Vitamins, minerals, nutritional supplements, herbs, and other natural products | |
| TWI405569B (en) | Oral formulation for the treatment of pigmentation symptoms in twice-daily administration | |
| US10485828B1 (en) | Nutritional supplement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |